Our experience with chemotherapeutic agents in the treatment of breast cancer.
We are reporting about 300 female patients with progressive breast cancer and metastases. One hundred them had been treated by single agent in 5 sub-groups consisting each of 20 patients. Their medial survival was 18.5 month in complete response (CR) patient. One hundred of the patients had 5-drugs chemotherapy with median survival in complete responders of 26 months. One hundred patients had a 5-drug combination chemotherapy including adriblastina with median survival for complete responders of 34 months. In the present work it is apparent that adriblastina prolongs the life of the patients. Our findings and the data of other investigators urge us to consider future experimental pilot protocols which will allow us to individualize treatment by defining for each patient the optimal mix of modalities and agents. We emphasize the use of tumor cell markers and ER receptors.
Bandouvas
T
T
Oncological Department-General State Hospital of Athens, Greece.
Koundouris
C
C
Kaspiris
A
A
Kallistros
A
A
Alexandridis
K
K
Kapellakis
Z
Z
Efthimiou
E
E
Taggalos
A
A
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D004317:Doxorubicin